These results indicated that IgSF11 could be considered as a negative prognostic marker in gliomas and that dual blocking of PD-1/IgSF11 pathways could be considered as promising future combined therapy for glioma patients. This evidence concerns the gene PDCD1 and central nervous system cancer.